Sanofi: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Sanofi said the European Commission approved an expanded indication for its MenQuadfi (MenACWY) vaccine in the EU, extending use to infants from six weeks of age against invasive meningococcal disease from serogroups A, C, W and Y. The change follows a positive CHMP opinion on June 25, 2026, and is supported by the MET58 study and a 2+1 infant schedule.
How this was made
The 30-second read
Why it matters
The expanded indication is supported by the MET58 pivotal study and a positive CHMP opinion dated June 25, 2026, giving healthcare providers flexibility to vaccinate within routine infant schedules.
Market read
A concrete EU regulatory milestone expands MenQuadfi’s eligible age range, which can improve addressable market for early-life meningococcal protection.
What to watch
Uptake depends on national immunization schedules, payer coverage, and whether clinicians switch from existing MenACWY options for the earliest infant window.
Background
MenQuadfi was previously approved in the EU for individuals aged 12 months and older; this approval extends the indication to infants from six weeks.
Ticker impact
Sanofi said the European Commission approved an expanded MenQuadfi indication for infants from six weeks, extending use beyond the prior 12-month cutoff.
Moderately positive near-term sentiment for Sanofi, with follow-through likely tied to uptake and any subsequent reimbursement or tender wins in EU markets.
The article is a first-report regulatory approval for a specific product indication, which is typically tradable for pharma vaccine franchises. However, it provides no revenue, uptake, or guidance impact figures, limiting conviction on magnitude.
Market effects
Adds incremental demand potential for meningococcal conjugate vaccines in Europe by enabling earlier infant vaccination.
EU immunization programs may adjust schedules and procurement for MenACWY coverage starting at six weeks.
Could strengthen Sanofi’s global vaccine positioning if similar label expansions follow in other jurisdictions.
Counterpoint
Regulatory approval alone may not translate into near-term earnings impact without clear reimbursement, tender timing, and competitive share gains.
Key entities
- companySanofi
Sponsor of MenQuadfi; announced EU approval for expanded infant indication.
- productMenQuadfi
Meningococcal Group A, C, W and Y conjugate vaccine; indication extended to infants from six weeks in the EU.
- regulatorEuropean Commission
Approved the extension of MenQuadfi’s indication in the EU.
- regulatorCHMP
Adopted a positive opinion on June 25, 2026 supporting the label expansion.
